RXDX
NASDAQPrometheus Biosciences Inc.
$199.93+0.21 (+0.11%)
Prometheus Biosciences Inc. (RXDX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for RXDX in the last 30 days. The most recent was published Oct 24, 2024.
Latest news
25 items- PRCellino Appoints Chris Gibson to Board of DirectorsCellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente
- SECSEC Form 15-12G filed by Prometheus Biosciences Inc.15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)
- PRMerck Completes Acquisition of Prometheus Biosciences, Inc.Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth
- INSIDERSEC Form 4 filed by Mckenna Mark C.4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Stenhouse Mark4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Hendrix Martin4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Laur James4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Papa Joseph C4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Swain Judith L4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Szela Mary T4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Marshall Keith W4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Hassan Fred4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Adams Helen C.4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- SECSEC Form 25-NSE filed by Prometheus Biosciences Inc.25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)
- SECSEC Form S-8 POS filed by Prometheus Biosciences Inc.S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)
- SECSEC Form S-8 POS filed by Prometheus Biosciences Inc.S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)
- SECSEC Form POSASR filed by Prometheus Biosciences Inc.POSASR - Prometheus Biosciences, Inc. (0001718852) (Filer)
- SECPrometheus Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Prometheus Biosciences, Inc. (0001718852) (Filer)
- SECPrometheus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Prometheus Biosciences, Inc. (0001718852) (Filer)
- SECSEC Form DEFA14A filed by Prometheus Biosciences Inc.DEFA14A - Prometheus Biosciences, Inc. (0001718852) (Filer)
- INSIDERSEC Form 4 filed by Mckenna Mark C.4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Marshall Keith W4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Stenhouse Mark4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- INSIDERSEC Form 4 filed by Papa Joseph C4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)
- SECSEC Form DEFA14A filed by Prometheus Biosciences Inc.DEFA14A - Prometheus Biosciences, Inc. (0001718852) (Filer)
RXDX FAQ
8 questionsWhat does Prometheus Biosciences Inc. do?
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics...What is the latest news on RXDX?
Quantisnow has not tracked any new filings, ratings or press releases for RXDX in the last 30 days. The most recent wire item was published on October 24, 2024.Where does RXDX stock trade?
Prometheus Biosciences Inc. (RXDX) is listed on NASDAQ.What sector and industry is RXDX in?
Prometheus Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Prometheus Biosciences Inc. go public?
Prometheus Biosciences Inc. (RXDX) completed its IPO in 2021.What are analysts saying about RXDX?
Across the last 8 analyst actions on Prometheus Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Jefferies: Hold with a $200.00 price target on 2023-05-10. Recent price targets range from $46.00 to $200.00.What companies are similar to RXDX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare RXDX side-by-side with any of them on Quantisnow.How can I track RXDX on Quantisnow?
Quantisnow aggregates Prometheus Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXDX to receive live email and push alerts on every new disclosure.